Abstract: Sustained release compositions comprising a drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.
Type:
Grant
Filed:
January 8, 1998
Date of Patent:
May 16, 2000
Assignee:
L.A.M. Pharmaceuticals, LLC
Inventors:
Alan Drizen, Peter Rothbart, Gary M. Nath
Abstract: Disclosed are methods of treating, inhibiting or preventing vascular thrombosis or arterial restenosis in a mammal. The disclosed methods include causing the mammal to inhale a therapeutically-effective concentration of gaseous nitric oxide (NO). Also disclosed are methods that include the administration of the following types of agents in conjunction with inhaled nitric oxide: compounds that potentiate the beneficial effects of inhaled nitric oxide, and antithrombotic agents that complement or supplement the beneficial effects of inhaled nitric oxide.
Abstract: A device is provided for the topical localized administration of zinc to tissue. The device comprises a central layer of absorbent material, with the central layer containing a mixture of particulate superabsorbent and zinc chloride that is sandwiched between a first and second layer of perforated polymeric film that is sealed at the edges. The device is activated by exposure to aqueous media prior to application to tissue. The quantity of zinc chloride contained in the device is varied according to the intended use. High levels of zinc chloride are used to form more concentrated solutions or gels for fixation of necrotic, gangrenous or cancerous tissue to facilitate excision or amputation while lower levels are used for more dilute solutions or gels to promote formation of granulation tissue and healing of lesions in non-necrotic tissue. The device is wrapped on the site to be treated or attached by adhesive means and is kept in place for a period appropriate to the intended use.
Abstract: A method for reducing coronary artery reactivity. A predetermined amount of natural progesterone is provided by a convenient and pleasant delivery system to the blood stream, sufficient to reduce the likelihood of coronary vasospasm and myocardial ischemia. The progesterone may be provided either by topical application to the epidermis of a cream in which the progesterone is dissolved or by patch technology, so as to provide continuous delivery and thereby maintain the level of progesterone in the blood stream at least about 1 nanogram per milliliter.
Abstract: The present invention provides emulsions, and a method for preparing emulsions, comprising (A) an aqueous phase, (B) an non-aqueous phase, and (C) (i) a proteinoid emulsifier, (ii) a modified hydrolyzed vegetable protein emulsifier wherein said modified hydrolyzed vegetable protein is modified with an amine reactive modifying agent, (iii) an acylated non-.alpha.-amino acid emulsifier, (iv) an acylated poly amino acid emulsifier, (v) an acylated peptide emulsifier, (vi) a sulfonated non-.alpha.-amino acid emulsifier, (vii) a sulfonated poly amino acid emulsifier, (viii) a sulfonated peptide emulsifier, or (ix) any combination of any of (i), (ii), (iii), (iv), (v), (vi), (vii), and (viii). The proteinoids, modified hydrolyzed vegetable proteins, modified non-.alpha.-amino acids, modified poly amino acids, and modified peptides used in the present invention provide emulsions having improved stability against degradation and/or decomposition.
Abstract: Low cost sunscreening formulations having SPF values greater than 40 contain homosalate, octyl salicylate or mixtures thereof, in combination with oxybenzone, and optionally further contain octyl methoxycinnamate, avobenzone or mixtures thereof.
Type:
Grant
Filed:
November 25, 1996
Date of Patent:
April 11, 2000
Assignee:
Schering-Plough HealthCare Products, Inc.
Abstract: A topical composition of a semi-solid consistency suitable is provided for transdermal application of prostaglandin E.sub.1. The composition comprises prostaglandin E.sub.1, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C.sub.1 to C.sub.8 alcohol, an aliphatic C.sub.8 to C.sub.30 ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.
Type:
Grant
Filed:
November 5, 1997
Date of Patent:
April 4, 2000
Assignee:
Nexmed Holdings, Inc.
Inventors:
Servet Buyuktimkin, Nadir Buyuktimkin, James Yeager
Abstract: Compounds of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are alkyl of 1-8 carbons have been shown to have both neuroprotective and analgesic activities. The compounds of the invention may be used in treatment of conditions that would normally result in neuronal damage, including those arising on account of cerebral ischemia/hypoxia or increase in intracranial pressure such as neoplasms, stroke, meningitis or trauma. Compositions of the invention can also be useful for treatment of toxin-related damage such as drug over-dose or exposure to toxins in the environment.
Type:
Grant
Filed:
January 20, 1998
Date of Patent:
April 4, 2000
Assignees:
The United States of America as represented by the Secretary of the Army, The United States of America as represented by the Department of Health and Human Services
Inventors:
Frank C. Tortella, Mark A. DeCoster, Kenner C. Rice, Sylvia N. Calderon
Abstract: The present invention relates to iodine demand disinfectants. It relates in particular to a process for preparing a polyiodide-resin for use as an iodine demand disinfectant wherein a porous strong base anion exchange resin in a salt form, is contacted with a material capable of donating a member absorbable by the resin so as to convert the resin to the polyiodide-resin. The adsorbable member is selected from the group comprising I.sub.2 and polyiodide ion having a valence of -1. The process is characterized in that conversion of the anion exchange resin to the polyiodide-resin is effected at elevated temperature and elevated pressure, the elevated temperature being 100 degrees C or higher, the elevated pressure being greater than atmospheric pressure. The present invention also relates to disinfectant substance comprising an iodine (impregnated) resin as produced by the above process.
Abstract: A composition and method for treating a wound with an inherently antimicrobial dressing. The dressing is a hydrogel containing from about 15 to 95 percent, and preferably from about 61 to 90 percent, by weight of a cationic quaternary amine acrylate polymer prepared by the polymerization of acryloyloxyethyl(or propyl)-trialkyl(or aryl)-substituted ammonium salts or acrylamidoethyl(or propyl)-trialkyl(or aryl)-substituted ammonium salts. The antimicrobial hydrogels are non-irritating to the wound, absorb wound exudate, and, due to the inherently antimicrobial properties, enhance the sterile environment around the wound. The hydrogels have sufficient adhesive properties that loose contact with the wound is assured but can also be removed without leaving any gel residue on the wound. The wound dressings are preferably formed on a substrate, such as a web or patch, for ease in application to and removal from the wound.
Abstract: The present invention is directed to a microsphere for the controlled release of a biologically active molecule which comprises a biologically active molecule and an ester of hyaluronic acid or mixtures of said esters of hyaluronic acids, and wherein said biologically active molecule is surrounded by or adhered to said ester of hyaluronic acid, and wherein said microsphere has a diameter of between 1 .mu.m to 100 .mu.m.
Abstract: Active ingredients such as medicines are mixed with excipient and then kneaded together with binder and solvent such as alcohol or water to prepare a wetted paste. A mold is filled with this paste. Top and bottom surfaces of the paste within the mold are coated with powder such as lubricant in order to avoid possible sticking of the paste to the apparatus during a subsequent compression step. Then a compressive pressure is exerted on the surface of the paste. Thereafter, the tablet is taken from the mold. The molded tablet can contain water-soluble or fat-soluble medicine.
Abstract: Topical gelled compositions comprising a drug for treating sexual dysfunction dispersed within a polymer matrix and methods and treatments using said compositions.
Type:
Grant
Filed:
March 26, 1998
Date of Patent:
March 14, 2000
Assignee:
L.A.M. Pharmaceutical Corp.
Inventors:
Alan Drizen, Peter Rothbart, Gary M. Nath
Abstract: A coated granular pesticide comprising a granular pesticide for use on plants which comprises at least one hardly water-soluble active ingredient and at least one water-swelling substance, and a thermoplastic resin-based film which covers the surface of the granular pesticide; a method for producing the same; and applications thereof. A surfactant, inorganic powder insoluble or hardly soluble in water, water-absorbing and/or water-soluble polymer fine powder, a thermosetting resin, or a biodegradable polymer insoluble or hardly soluble in water, or a combination thereof may be incorporated into the film.
Abstract: Dental composites are provided on the basis of customary polymerizable monomers, initiators, fillers and other auxiliaries, which additionally contain the plaque-inhibiting addition of salts of acid-functional polymers having mono- or polyvalent cations.
Abstract: A controlled absorption diltiazem pellet formulation for oral administration comprises a core having diltiazem or a pharmaceutically acceptable salt thereof as the active ingredient. The core is surrounded by a coating which has only a single layer which is comprised of a relatively major proportion of talc and relatively minor proportion of sodium lauryl sulfate admixed with a minor proportion of a pharmaceutically acceptable film-forming, first polymer permeable to water and diltiazem, and a major proportion of a pharmaceutically acceptable film-forming, second polymer that is less permeable to water and diltiazem than the first polymer. The core and the coating layer both exclude organic acids. The composition of the coating layer as well as the proportion of core to coating layer are effective to permit release of the diltiazem allowing controlled absorption following oral administration.
Type:
Grant
Filed:
April 7, 1999
Date of Patent:
March 7, 2000
Assignee:
F.H. Faulding & Co.
Inventors:
Grant W. Heinicke, Angelo Lepore, Angelo M. Morella
Abstract: The present invention relates to novel liquid oral suspensions incorporated within a soft gelatin capsule comprised of a bitter or bad-tasting pharmaceutical active (such as antihistamines, decongestants and the like) which is dispersed within an adsorbate comprised of magnesium trisilicate, silicon dioxide or mixture thereof. The adsorbate is dispersed within an aqueous or non-aqueous carrier base and combined with other flavors, sweeteners, emulsifiers and the like. The adsorbate not only taste-masks the active but also insures that is evenly dispersed through the liquid suspension so that a uniform dosage rate is readily achievable. The encapsulation of the adsorbate within a gelatin capsule makes administration easier for children andmore convenient. The capsule also affords the adsorbate suspension greater shelf life.
Abstract: Rinse-off, water-in-oil-in-water multiple emulsion compositions are disclosed. The multiple emulsion compositions comprise an external aqueous phase optionally incorporating an emulsifier and/or a second topically-active compound. The internal phase comprises a primary water-in-oil emulsion, wherein the primary emulsion comprises a first topically-active compound, a surfactant phase, an oil phase, and water.
Type:
Grant
Filed:
June 28, 1996
Date of Patent:
February 8, 2000
Assignee:
Helene Curtis, Inc.
Inventors:
Craig A. Herb, Liang Bin Chen, Judy Chung, Michelle A. Long, Wei Mei Sun, Gerald P. Newell, Trefor A. Evans, Kimberly Kamis, Richard M. Brucks
Abstract: The present invention is a method and a dosage unit for delivery of a controlled-release system. The dosage unit is a quick dissolve unit which can be prepared by mixing uncured shearform matrix and a controlled-release system, either molding or compacting a unit dosage form and curing the shearform matrix. The controlled-release systems used in the present invention include instantaneous release components, delayed release components, sustained release components, and combinations thereof.
Type:
Grant
Filed:
November 5, 1997
Date of Patent:
February 1, 2000
Assignee:
Fuisz Technologies Ltd.
Inventors:
Garry L. Myers, Gerald E. Battist, Richard C. Fuisz
Abstract: A cosmetic composition for application to the skin, the semimucosae and/or the mucosae, including a polymeric system which includes an aqueous dispersion of particles of film-forming polymer, wherein the polymeric system makes it possible to obtain a supple and flexible film.